Information  X 
Enter a valid email address

MyCelx Tech. Corp. (MYX)

  Print      Mail a friend

Friday 07 December, 2018

MyCelx Tech. Corp.

Block Admission Interim Update

RNS Number : 7480J
MyCelx Technologies Corporation
07 December 2018
 

MyCelx Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

 

7 December 2018

 

 

 

Block Admission Interim Update

 

In respect of the block admissions to trading on AIM on 29 April 2013 and 3 October 2017 for MYCELX common shares of US$0.025 each ("Shares"), MYCELX provides the following update in respect of the period 7 June 2018 to 6 December 2018 (the "Period").

 

 

Omnibus Performance Incentive Plan 2011                              No of Shares                     

                                   

Admitted on 29 April 2013                                               300,000

Admitted on 3 October 2017                                           300,000

Issued prior to the Period                                               (333,198)

Issued during the Period                                                      -

                                                                                                    ------------

Shares not yet issued                                                                  266,802

                                                                                                     =======

 

 

 

 

Enquiries:

 

MYCELX Technologies Corporation                                                   +1 888 306 6843

Kimberly Slayton, Chief Financial Officer

 

Cantor Fitzgerald Europe

Nominated Adviser and Broker

David Porter

Richard Salmond                                                                                  +44 207 894 7000

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
STRUGGGGPUPRPGQ

a d v e r t i s e m e n t